---
title: "Weekly Recap | Adma Biologics -4.05%, rally fades into pullback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298799124.md"
description: "Adma Biologics (ADMA) fell 4.05% this week to close at $9.23 on Friday, while the S&P 500 slipped 0.8%, leaving the stock about 3.25 percentage points behind the benchmark. The four-session week opened at $9.51 on Tuesday and hit a weekly high of $9.65 before fading into Friday’s low of $9.195, a classic rally that gave way to selling pressure."
datetime: "2026-09-12T07:41:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298799124.md)
  - [en](https://longbridge.com/en/news/298799124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298799124.md)
generator: "portal-rs"
---

# Weekly Recap | Adma Biologics -4.05%, rally fades into pullback

## The Week

Adma Biologics (ADMA) fell 4.05% this week to close at $9.23 on Friday, while the S&P 500 slipped 0.8%, leaving the stock about 3.25 percentage points behind the benchmark. The four-session week opened at $9.51 on Tuesday and hit a weekly high of $9.65 before fading into Friday’s low of $9.195, a classic rally that gave way to selling pressure. There were no major business catalysts; the only news item was a law firm’s investigation into the board’s fiduciary duties, a governance-related matter.

## Analyst Ratings

ADMA currently has 4 covering firms: 2 rate it buy, 1 overweight and 1 hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $17 sits about 84.2% above the latest price of $9.23. Targets range from $12 to $21, showing meaningful dispersion. Among 506 biotechnology companies, ADMA’s rating rank is 308, placing it in the lower-middle tier.

## The Week Ahead

ADMA has no earnings of its own scheduled next week, so the focus shifts to US macro data. The New York Fed manufacturing index lands on Tuesday 15 September, followed on Wednesday 16 September by retail sales, retail sales ex-autos, import prices and the NAHB housing market index. These releases will shape the broader risk appetite for biotech names and are worth tracking alongside ADMA.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md)

## Related News & Research

- [ADMA Biologics Study Shows Optimized IVIG Process Removes Impurities Linked to Thrombosis Risk](https://longbridge.com/en/news/301967470.md)
- [WINTON GROUP Ltd Lowers Stock Holdings in ADMA Biologics Inc $ADMA](https://longbridge.com/en/news/299519394.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.](https://longbridge.com/en/news/302948213.md)
- [Hanseatic Management Services Inc. Buys New Stake in Marvell Technology, Inc. $MRVL](https://longbridge.com/en/news/302958015.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**